In conclusion, while CD70 would appear to be a promising target in the treatment of R/R NHL, the applicability of SGN-CD70A is limited by the frequency and severity of thrombocytopenia, despite the long-term of response with limited drug exposure. This evidence concerns the gene CD70 and non-Hodgkin lymphoma.